Evidence map›Paper›PMID 40931046›Full record

ArticleLeukemia2025

A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia.

Magdalini Kanari, Iria Jimenez Garcia, Fabio D Steffen, Lisa A Krattiger, Charles Bataclan, Wangjie Liu, Benjamin R Simona, Bart Deplancke, Olaia Naveiras, Martin Ehrbar and 2 more

Abstract read
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Magdalini KanariUniversity Children's Hospital Zurich, Pediatric Oncology and Children's Research Center, Zurich, Switzerland.
Iria Jimenez GarciaUniversity Children's Hospital Zurich, Pediatric Oncology and Children's Research Center, Zurich, Switzerland.ORCID 0000-0002-4251-4232
Fabio D SteffenUniversity Children's Hospital Zurich, Pediatric Oncology and Children's Research Center, Zurich, Switzerland.ORCID 0000-0001-8795-2212
Lisa A KrattigerUniversity Hospital Zurich, Department of Obstetrics, Zurich, Switzerland.ORCID 0000-0002-6309-5436
Charles BataclanLaboratory of Regenerative Hematopoiesis, Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.
Wangjie LiuLaboratory of Systems Biology and Genetics, Institute of Bio-Engineering & Global Health Institute, School of Life Sciences, EPFL, Lausanne, Switzerland.ORCID 0000-0002-0801-1164
Benjamin R SimonaECTICA Technologies AG, Zurich, Switzerland.
Bart DeplanckeLaboratory of Systems Biology and Genetics, Institute of Bio-Engineering & Global Health Institute, School of Life Sciences, EPFL, Lausanne, Switzerland.ORCID 0000-0001-9935-843X
Olaia NaveirasLaboratory of Regenerative Hematopoiesis, Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-3434-0022
Martin EhrbarUniversity Hospital Zurich, Department of Obstetrics, Zurich, Switzerland.ORCID 0000-0003-2707-4870
Beat BornhauserUniversity Children's Hospital Zurich, Pediatric Oncology and Children's Research Center, Zurich, Switzerland.ORCID 0000-0003-2890-3191
Jean-Pierre BourquinUniversity Children's Hospital Zurich, Pediatric Oncology and Children's Research Center, Zurich, Switzerland. jean-pierre.bourquin@kispi.uzh.ch.ORCID 0000-0001-6571-6227

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) CRSII5_186271Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) CRSII5_186271 [Deplancke][Bourquin]Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) CRSII5_186271 [Ehrbar][Bourquin]Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) CRSII5_186271 [Naveiras][Bourquin]
6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) preferentially localizes in the bone marrow (BM) and displays recurrent patterns of medullary and extra-medullary involvement. Leukemic cells exploit their niche for propagation and survive selective pressure by chemotherapy in the BM microenvironment, suggesting the existence of protective mechanisms. Here, we established a three-dimensional (3D) BM mimic with human mesenchymal stromal cells and endothelial cells that resemble vasculature-like structures to explore the interdependence of leukemic cells with their microenvironment. This model recapitulates recurrent topologic differences between B-cell and T-cell precursor ALL, whereby B-ALL interacts more closely with the mesenchymal compartment. Migration versatility was found to be associated with subtype, consistent with increased motility observed in T-ALL in vivo. Single-cell RNA signatures revealed similarities to profiles from in vivo patient derived xenografts, suggesting relevant states ex vivo. Furthermore, enhanced migration, adherence and cell cycle heterogeneity was visualized in our co-culture model. Finally, drug response experiments in this 3D model confirm clinically relevant sensitivity and resistance patterns that reflect specific disease phenotypes and may provide a broader dynamic range for drug response testing.

Indexed as

Drug Resistance, NeoplasmPrecursor Cell Lymphoblastic Leukemia-LymphomaAnimalsBone MarrowCell MovementChildCoculture TechniquesHumansMesenchymal Stem CellsMicePhenotypeTumor Cells, CulturedTumor MicroenvironmentXenograft Model Antitumor Assays

Identifiers

PMID40931046
PMCPMC12634434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.